An overview of myelodysplastic syndromes.
Journal
JAAPA : official journal of the American Academy of Physician Assistants
ISSN: 1547-1896
Titre abrégé: JAAPA
Pays: United States
ID NLM: 9513102
Informations de publication
Date de publication:
01 06 2023
01 06 2023
Historique:
medline:
29
5
2023
pubmed:
10
5
2023
entrez:
10
5
2023
Statut:
ppublish
Résumé
Myelodysplastic syndromes (MDS) can present as a cytopenia-often as unexplained anemia. Because MDS can progress to acute myelogenous leukemia, primary care providers should be aware of the signs and symptoms, which are associated with the corresponding cytopenia that patients experience and may include fatigue, infection, easy bruising, and bleeding. Treatment options center on managing related cytopenias. The only cure, stem cell transplant, is not readily available.
Identifiants
pubmed: 37163704
doi: 10.1097/01.JAA.0000931428.87936.72
pii: 01720610-202306000-00003
doi:
Types de publication
Journal Article
Langues
eng
Pagination
17-21Informations de copyright
Copyright © 2023 American Academy of Physician Associates.
Références
Mohammad AA. Myelodysplastic syndrome from theoretical review to clinical application view. Oncol Rev . 2018;12(2):397.
Menssen AJ, Walter MJ. Genetics of progression from MDS to secondary leukemia. Blood . 2020;136(1):50–60.
National Cancer Institute. Surveillance, epidemiology, and end results program. https://seer.cancer.gov/statistics-network/explorer/application.html . Accessed March 18, 2023.
Montoro J, Yerlikaya A, Ali A, Raza A. Improving treatment for myelodysplastic syndromes patients. Curr Treat Options Oncol . 2018;19(12):66.
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood . 2016;127(20):2391–2405.
Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood . 2012;120(12):2454–2465.
Cazzola M. Myelodysplastic syndromes. N Engl J Med . 2020;383(14):1358–1374.
Adès L, Itzykson R, Fenaux P. Myelodysplastic syndromes. Lancet . 2014;383(9936):2239–2252.
Kuendgen A, Nomdedeu M, Tuechler H, et al. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS. Leukemia . 2021;35(3):835–849.
Grignano E, Jachiet V, Fenaux P, et al. Autoimmune manifestations associated with myelodysplastic syndromes. Ann Hematol . 2018;97(11):2015–2023.
Albert DA, Burns CM. Rheumatologic manifestations in myelodysplastic syndrome. J Clin Rheumatol . 2012;18(3):148–150.
Fozza C, Crobu V, Isoni MA, Dore F. The immune landscape of myelodysplastic syndromes. Crit Rev Oncol Hematol . 2016;107:90–99.
Wolach O, Stone R. Autoimmunity and inflammation in myelodysplastic syndromes. Acta Haematol . 2016;136(2):108–117.
Tsagarakis NJ, Paterakis G, Papadhimitriou SI, et al. Bone marrow aspirate automated counts on hematology analyzers: formulating a scoring system based on hematology parameters, to discriminate reactive versus myelodysplastic syndrome-related bone marrows. Int J Lab Hematol . 2019;41(4):542–549.
Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis . 2011;52(4):e56–e93.
Valent P, Orazi A, Steensma DP, et al. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget . 2017;8(43):73483–73500.
Cross NCP, Godfrey AL, Cargo C, et al. The use of genetic tests to diagnose and manage patients with myeloproliferative and myeloproliferative/myelodysplastic neoplasms, and related disorders. Br J Haematol . 2021;195(3):338–351.
Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood . 2009;114(5):937–951.
Platzbecker U. Treatment of MDS. Blood . 2019;133(10):1096–1107.
Bewersdorf JP, Carraway H, Prebet T. Emerging treatment options for patients with high-risk myelodysplastic syndrome. Ther Adv Hematol . 2020;11:1–22.
Shallis RM, Zeidan AM. Management of the older patient with myelodysplastic syndrome. Drugs Aging . 2021;38(9):751–767.
Loingsigh SN, Flegel WA, Hendrickson JE, Tormey CA. Preventing transfusion-associated graft-versus-host disease with blood component irradiation: indispensable guidance for a deadly disorder. Br J Haematol . 2020;191(5):653–657.